Actively Recruiting
Repletion of Ergothioneine in Patients With Kidney Failure
Led by Stanford University · Updated on 2026-04-01
28
Participants Needed
1
Research Sites
295 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.
CONDITIONS
Official Title
Repletion of Ergothioneine in Patients With Kidney Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have kidney failure and receive hemodialysis or peritoneal dialysis
You will not qualify if you...
- Have had a blood transfusion within the past 90 days
- Are currently taking supplements that contain ergothioneine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Veterans Affairs Palo Alto
Palo Alto, California, United States, 94304
Actively Recruiting
Research Team
T
Tammy Sirich, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here